Open Access
Open access
том 13 издание 8 страницы 1157

Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders

Тип публикацииJournal Article
Дата публикации2021-07-27
SCImago Q1
Tоп 10% SCImago
WOS Q1
БС1
SJR1.197
CiteScore10
Impact factor5.5
ISSN19994923
Pharmaceutical Science
Краткое описание

Nanomaterials provide enormous opportunities to overcome the limitations of conventional ocular delivery systems, such as low therapeutic efficacy, side effects due to the systemic exposure, or invasive surgery. Apart from the more common ocular disorders, there are some genetic diseases, such as cystic fibrosis, that develop ocular disorders as secondary effects as long as the disease progresses. These patients are more difficult to be pharmacologically treated using conventional drug routes (topically, systemic), since specific pharmacological formulations can be incompatible, display increased toxicity, or their therapeutic efficacy decreases with the administration of different kind of chemical molecules. Magnetic nanoparticles can be used as potent drug carriers and magnetic hyperthermia agents due to their response to an external magnetic field. Drugs can be concentrated in the target point, limiting the damage to other tissues. The other advantage of these magnetic nanoparticles is that they can act as magnetic resonance imaging agents, allowing the detection of the exact location of the disease. However, there are some drawbacks related to their use in drug delivery, such as the limitation to maintain efficacy in the target organ once the magnetic field is removed from outside. Another disadvantage is the difficulty in maintaining the therapeutic action in three dimensions inside the human body. This review summarizes all the application possibilities related to magnetic nanoparticles in ocular diseases.

Для доступа к списку цитирований публикации необходимо авторизоваться.
Для доступа к списку профилей, цитирующих публикацию, необходимо авторизоваться.

Топ-30

Журналы

1
2
3
International Journal of Pharmaceutics
3 публикации, 3.61%
Expert Opinion on Drug Delivery
3 публикации, 3.61%
European Journal of Pharmaceutics and Biopharmaceutics
3 публикации, 3.61%
International Journal of Molecular Sciences
2 публикации, 2.41%
Pharmaceutics
2 публикации, 2.41%
Journal of Materials Chemistry B
2 публикации, 2.41%
Advanced healthcare materials
2 публикации, 2.41%
Journal of Controlled Release
2 публикации, 2.41%
Gels
1 публикация, 1.2%
Materials
1 публикация, 1.2%
Journal of Pharmaceutical Investigation
1 публикация, 1.2%
Materials Today Chemistry
1 публикация, 1.2%
Journal of Drug Delivery Science and Technology
1 публикация, 1.2%
Journal of Molecular Structure
1 публикация, 1.2%
Cancers
1 публикация, 1.2%
Environmental Science and Pollution Research
1 публикация, 1.2%
Polymers
1 публикация, 1.2%
Hybrid Advances
1 публикация, 1.2%
Emergent Materials
1 публикация, 1.2%
Pharmaceuticals
1 публикация, 1.2%
Pathogens and Global Health
1 публикация, 1.2%
AIP Conference Proceedings
1 публикация, 1.2%
Frontiers in Pharmacology
1 публикация, 1.2%
Biosensors
1 публикация, 1.2%
Journal of the American Chemical Society
1 публикация, 1.2%
Proceedings of the National Academy of Sciences of the United States of America
1 публикация, 1.2%
Molecular Diversity
1 публикация, 1.2%
Journal of Drug Targeting
1 публикация, 1.2%
Current Diabetes Reviews
1 публикация, 1.2%
1
2
3

Издатели

5
10
15
20
25
Elsevier
23 публикации, 27.71%
MDPI
13 публикаций, 15.66%
Springer Nature
13 публикаций, 15.66%
Taylor & Francis
8 публикаций, 9.64%
Wiley
5 публикаций, 6.02%
Royal Society of Chemistry (RSC)
4 публикации, 4.82%
Bentham Science Publishers Ltd.
3 публикации, 3.61%
Frontiers Media S.A.
2 публикации, 2.41%
AIP Publishing
1 публикация, 1.2%
American Chemical Society (ACS)
1 публикация, 1.2%
Proceedings of the National Academy of Sciences (PNAS)
1 публикация, 1.2%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 1.2%
Institute of Electrical and Electronics Engineers (IEEE)
1 публикация, 1.2%
openRxiv
1 публикация, 1.2%
Oxford University Press
1 публикация, 1.2%
Apex Publishing
1 публикация, 1.2%
PeerJ
1 публикация, 1.2%
A and V Publications
1 публикация, 1.2%
Pleiades Publishing
1 публикация, 1.2%
5
10
15
20
25
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
 Войти с ORCID
Метрики
83
Поделиться
Цитировать
ГОСТ |
Цитировать
Schneider-Futschik E. K., Reyes-Ortega F. Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders // Pharmaceutics. 2021. Vol. 13. No. 8. p. 1157.
ГОСТ со всеми авторами (до 50) Скопировать
Schneider-Futschik E. K., Reyes-Ortega F. Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders // Pharmaceutics. 2021. Vol. 13. No. 8. p. 1157.
RIS |
Цитировать
TY - JOUR
DO - 10.3390/pharmaceutics13081157
UR - https://doi.org/10.3390/pharmaceutics13081157
TI - Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders
T2 - Pharmaceutics
AU - Schneider-Futschik, Elena K.
AU - Reyes-Ortega, Felisa
PY - 2021
DA - 2021/07/27
PB - MDPI
SP - 1157
IS - 8
VL - 13
PMID - 34452117
SN - 1999-4923
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2021_Schneider-Futschik,
author = {Elena K. Schneider-Futschik and Felisa Reyes-Ortega},
title = {Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders},
journal = {Pharmaceutics},
year = {2021},
volume = {13},
publisher = {MDPI},
month = {jul},
url = {https://doi.org/10.3390/pharmaceutics13081157},
number = {8},
pages = {1157},
doi = {10.3390/pharmaceutics13081157}
}
MLA
Цитировать
Schneider-Futschik, Elena K., and Felisa Reyes-Ortega. “Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders.” Pharmaceutics, vol. 13, no. 8, Jul. 2021, p. 1157. https://doi.org/10.3390/pharmaceutics13081157.
Ошибка в публикации?